NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims against Rockwell Medical, Inc. (NASDAQ: RMTI). Our investigation concerns whether Rockwell Medical has violated the federal securities laws and/or engaged in other unlawful business practices.
On May 22, 2018, after the market had closed, Rockwell Medical announced that the Company’s President and Chief Executive Officer, Robert Chioini, had been terminated from his positions, effective immediately.
However, on May 23, 2018, a letter was published by the Company, signed by Mr. Chioini, explaining that he had called an emergency Board meeting for the purpose of discussing alleged breaches of fiduciary duties and other possible violations of securities laws by various directors the Company. The letter further asserted that those directors whose conduct was the subject of the alleged breaches of fiduciary duties voted to fire Mr. Chioini.
Following this news, Nasdaq suspended trading of Rockwell Medical securities.
If you purchased or otherwise acquired Rockwell Medical shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Rockwell Medical, Inc., please go to http://www.bespc.com/rmti. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
